







Beth Israel Lahey Health Inhaler Selection Guide – Summary

Updated 4/2021

The following information is designed to guide and inform prescribers on the selection of different inhalers for ambulatory patients at the point of prescribing. Preference for different agents shown is based on which agents are most widely covered by major commercial payors (BCBS, HPHC, and Tufts) across the BILH Network, it **does not imply clinical preference**. This information does not apply to all commercial products, nor does it apply to Medicare Part D patients. Refer to individual insurance plan information for other commercial and Part D plans.

Document Content (Quick Links)

 Section 1	 Section 2	 Section 3	 Section 4	 Section 5	 Section 6
Determine Inhaler Class	Determine Ins. Coverage	Determine Device	Determine Potency/Dose	Educate Patient	Reassess

Quick View: Consider these first (based on insurance coverage and lowest cost)

Write for Brand name agents and allow for generic substitution where available.

Where Brand is preferred, do not write No Substitution. This will allow the pharmacy to choose what is covered by the plan.

Commercial Plans (BCBS, HPHC, Tufts)		MassHealth (including ACO: THPP, BMC)	
Short-acting beta agonist (SABA) inhalers			
DPI	*	ProAir Respiclick	
MDI	ProAir HFA (<i>allow generic substitution</i>)	ProAir HFA <u>brand</u>	
Inhaled Corticosteroids (ICS)			
DPI	Arnuity Ellipta	Flovent Diskus	
MDI	Flovent HFA	Flovent HFA	
Long-Acting Beta-Agonists (LABA)			
DPI	Serevent Diskus	*	
MDI	Striverdi Respimat	Striverdi Respimat	
Inhaled corticosteroid/Long-acting beta agonist (ICS/LABA)			
DPI	AirDuo Respiclick (Preferred) (<i>allow generic substitution</i>) OR Advair Diskus (<i>allow generic substitution</i>)	Advair Diskus <u>brand</u>	
MDI	Symbicort	Symbicort	
Long-Acting Muscarinic Antagonist (LAMA)			
DPI	Spiriva Handihaler	Spiriva Handihaler	
MDI	Spiriva Respimat	Spiriva Respimat	
Long-acting muscarinic antagonist/beta agonist (LAMA/LABA)			
DPI	Anoro Ellipta	Anoro Ellipta	
MDI	Stiolto Respimat	*	
Triple therapy (LAMA/LABA/ICS)			
DPI	*	None are covered	
MDI	None are covered	None are covered	

DPI = Dry-powder inhaler | MDI = Metered-dose inhaler | BCBS = Blue Cross Blue Shield | HPHC = Harvard Pilgrim Health Care
 THPP = Tufts Health Public Plans | BMC = BMC HealthNet | * no single agent is universally covered, please see individual plan coverage

Beth Israel Lahey Health Inhaler Selection Guide – Details







Updated 4/2021

There is little clinical difference between inhalers within the same class, so choosing the inhaler that is easiest for patients to successfully use is the most important factor when selecting an inhaler.

Asthma and COPD are very expensive disease states with costs driven largely by healthcare utilization and medication cost. Despite the high cost, inhalers can help drive down the overall cost of disease management by reducing healthcare utilization in the form of emergency department visits and hospitalizations. For this reason, proper adherence to inhalers is vital from the perspective of both patient care and reduction in total medical expenditure (TME).

Ensuring proper inhaler adherence starts at the point of prescribing and should continue with each follow-up appointment. Adherence to inhaler therapy is often challenging due to constraints such as insurance coverage, cost, and proper technique. Identifying the most appropriate inhaler at the point of prescribing is important for patient engagement. This document is designed to guide in the decision-making process for determining which inhaler patients are most likely to successfully adhere to.

Document outline – click on the links below to be directed to the desired topic

-  Section 1
 Section 2
 Section 3
 Section 4
 Section 5
 Section 6

Choose the inhaler class	Determine Insurance Coverage	Determine delivery device	Determine potency and dose	Educate patient	Reassess
<p>ICS or ICS/LABA</p> <ul style="list-style-type: none"> • Considerations • Inhaler chart <p>LAMA, LABA, or LAMA/LABA</p> <ul style="list-style-type: none"> • Considerations • Inhaler chart 	<p>Coverage Tips (see most recent BILH Inhaler Coverage and Preference Chart for plan-specific coverage info)</p>	<p>Decision Guide and List of Devices</p>	<p><i>(Refers to ICS only)</i></p> <p>General Considerations</p> <p>ICS Dose Comparison Chart</p> <p>ICS/LABA Dose Comparison Chart</p>	<p>Review Proper Inhaler Technique</p>	<p>General Considerations</p> <p>Reassessment Cycle</p> <p>Reassessment Reference Chart</p>

ICS = Inhaled Corticosteroid

LABA = Long-Acting Beta Agonist

LAMA = Long-Acting Muscarinic Antagonists

[Return to Page 1](#)

Section 1

Choose the most appropriate inhaler class for the patient

Considerations for ICS and ICS/LABA		
	Asthma*	COPD**
General considerations	<ul style="list-style-type: none"> There is no clinical difference in the effectiveness of different ICS or ICS/LABA inhalers within each class when used at appropriate comparative doses Identifying the minimum effective ICS dose for all patients is important for minimizing risk of adverse effects, including pneumonia, in both asthma and COPD Patients must be counseled to rinse their mouth and/or brush their teeth immediately after each use to prevent thrush and minimize bad taste 	
Inhaled corticosteroids (ICS)	<ul style="list-style-type: none"> ICS is the backbone of asthma therapy based on data showing reductions in exacerbations, hospitalizations, and mortality 	<ul style="list-style-type: none"> Not recommended as monotherapy for COPD
Inhaled corticosteroids/long-acting beta agonists (ICS/LABA)	<ul style="list-style-type: none"> For patients not well-controlled on ICS alone, combination with LABA can reduce symptoms and exacerbations while also potentially limiting need for higher doses of ICS 	<ul style="list-style-type: none"> ICS/LABA may reduce exacerbations in patients not well-controlled with LAMA or LABA monotherapy

*Based on recommendations from the Global Initiative for Asthma (GINA) 2020 Report

**Based on the Global Initiative for Chronic Obstructive Lung Disease 2021 GOLD Report

List of ICS and ICS/LABA inhalers			
Drug Class	Brand Name	Active Ingredient	FDA-Approved Indication(s)
Inhaled corticosteroid (ICS) inhalers	Alvesco HFA	ciclesonide	Asthma
	ArmonAir Digihaler	fluticasone propionate	Asthma
	Arnuity Ellipta	fluticasone furoate	Asthma
	Asmanex HFA	mometasone	Asthma
	Asmanex Twisthaler	mometasone	Asthma
	Flovent Diskus/HFA	fluticasone propionate	Asthma
	Pulmicort Flexhaler	budesonide	Asthma
	QVAR Redihaler	beclomethasone	Asthma
Inhaled corticosteroid/Long-acting beta agonist (ICS/LABA) inhalers	Advair Diskus*	fluticasone/salmeterol	Asthma, COPD
	Advair HFA	fluticasone/salmeterol	Asthma
	AirDuo Resplick*	fluticasone/salmeterol	Asthma
	Breo Ellipta	fluticasone furoate/vilanterol	Asthma, COPD
	Dulera HFA	mometasone/formoterol	Asthma
	Symbicort HFA*	budesonide/formoterol	Asthma, COPD
	Wixela Inhub*	fluticasone/salmeterol	Asthma, COPD

*Generically available

[Return to Page 1](#)

Considerations for LAMA, LABA, combination (LAMA/LABA), and triple therapy (LAMA/LABA/ICS)		
	Asthma*	COPD**
General considerations	<ul style="list-style-type: none"> There is generally no clinical difference in the effectiveness of different inhalers within each class, although only select LAMA agents are indicated for asthma management Once initiated, LAMA and LABA inhalers do not require dose adjustments as each product is available as a single strength No maintenance inhaler alone or in combination has shown significant mortality benefit for COPD patients 	
Long-acting muscarinic antagonists (LAMA)	<ul style="list-style-type: none"> Not recommended as monotherapy for asthma patients 	<ul style="list-style-type: none"> Recommended as first-line bronchodilator therapy. More effective than LABA monotherapy for reduction of exacerbations and hospitalizations
Long-acting beta agonists (LABA)	<ul style="list-style-type: none"> LABA monotherapy is <u>contraindicated</u> in asthma and must only be used in a combination inhaler with ICS 	<ul style="list-style-type: none"> LABA monotherapy can be initiated in patients at low risk for exacerbations or in which LAMA monotherapy is not recommended
Long-acting muscarinic antagonist/beta agonist (LAMA/LABA)	<ul style="list-style-type: none"> LAMA/LABA combination inhalers are not recommended for asthma patients as they should only be used alongside an ICS 	<ul style="list-style-type: none"> Use of LAMA/LABA in combination has been shown to improve symptoms and exacerbations more than either agent used as monotherapy
Triple therapy (LAMA/LABA/ICS)	<ul style="list-style-type: none"> Select LAMA agents, when used in addition to or in combination with ICS/LABA, can improve lung function and decrease exacerbations 	<ul style="list-style-type: none"> Triple therapy can be used for further reduction in symptoms and exacerbations compared to any other mono or combination therapy

*Based on recommendations from the Global Initiative for Asthma (GINA) 2020 Report

**Based on the Global Initiative for Chronic Obstructive Lung Disease 2021 GOLD Report

List of LAMA, LABA, combination (LAMA/LABA), and triple therapy (LAMA/LABA/ICS) inhalers

Drug Class	Brand Name	Active Ingredients	FDA-Approved Indication(s)
Long-acting muscarinic antagonist (LAMA)	Incruse Ellipta	umeclidinium bromide	COPD
	Seebri Neohaler	glycopyrrolate	COPD
	Spiriva Handihaler/Respimat	tiotropium bromide	Asthma*, COPD
	Tudorza Pressair	acildinium bromide	COPD
Long-acting beta agonist (LABA)	Arcapta Neohaler	indacaterol	COPD
	Serevent Diskus	salmeterol	COPD
	Striverdi Respimat	olodaterol	COPD
Long-acting muscarinic antagonist/beta agonist (LAMA/LABA)	Anoro Ellipta	umeclidinium/vilanterol	COPD
	Bevespi Aerosphere	glycopyrrolate/formoterol	COPD
	Stiolto Respimat	tiotropium/olodaterol	COPD
	Utibron Neohaler	glycopyrrolate/indacaterol	COPD
	Duaklir Pressair	aclidinium/formoterol	COPD
Triple therapy (LAMA/LABA/ICS)	Trelegy Ellipta	umeclidinium/vilanterol/fluticasone furoate	Asthma, COPD
	Breztri Aerosphere	glycopyrrolate/formoterol/ budesonide	COPD

*Only Respimat device is approved for asthma

[Return to Page 1](#)

Section 2
Determine which options are covered by the patient’s insurance

Please see the most recent *BILH Inhaler Coverage Chart* for plan-specific coverage information


Insurance coverage tips for inhalers	
Tips	Rationale
Before submitting a prior authorization for a non-covered product, consider covered alternative options within the patient’s plan	Prior authorizations can lead to higher costs for both patients and healthcare systems. They can also be time-consuming for office staff.
Instruct patients to contact their prescriber’s office if the inhaler is not covered, the copayment is too high, or the inhaler is not available at the pharmacy.	Coverage information is subject to change and may vary based on the patient’s individual plan. In order to find the inhaler that patients will most likely be able to successfully adhere to, they must be forthcoming when concerns arise. Letting them know about these potential issues in advance and advising them on how to proceed will help keep them engaged.
If unsure what a patient’s insurance covers: <ul style="list-style-type: none"> • select the brand name but DO NOT write “No Substitution” • An alternative would be to select the generic name of the inhaler with a note to the pharmacy to dispense the product that is preferred by the patient’s insurance 	With the addition of generic inhalers to the market, these may automatically substitute at the pharmacy. Where some insurance plans still prefer brand-name products, pharmacies (in most cases) will dispense what is covered by the insurance based on alerts when processing the Rx.

[Return to Page 1](#)

Section 3

Determine which inhaler device is most appropriate

Once a patient's options are narrowed down based on insurance coverage, inhaler selection may be further refined based on which inhaler device is easiest for patients to use. Considerations for determining which inhaler device is most appropriate comes down to three main areas: **Breath**, **Dexterity** and **Strength**



Inhaler Complexity						
DPI	<ul style="list-style-type: none"> Activated by the patient's breath. Medication is delivered to the lungs with a quick, deep breath in. Requires that the patient is able to take a deep, quick breath in within 2-3 seconds to ensure proper drug delivery. Preferable in patients with coordination issues relative to metered dose inhalers. 					
	Ellipta Respiclick Twisthaler	Diskus Inhub	Flexhaler Pressair ¹		Handihaler ¹ Neohaler ¹	
Number of steps per dose						
MDI	<ul style="list-style-type: none"> Release medication upon pressing a button. The medication is propelled by the device itself, as opposed to being activated by the patient's breath. Does not require the patient to take a deep, quick breath as with the DPIs. Requires some level of coordination as the patient must take a breath in while also pressing the button to release the medication at the same time. Can be used with a spacer for patients that cannot use a DPI and may struggle to coordinate the timing of medication delivery. 					
	Redihaler Respimat ^{1,2}	Aerosphere ¹ HFA ¹				

¹Potentially difficult for patients with weak, shaky, and/or painful hands, ²Additional steps required prior to first use

Section 4

Choose the most appropriate dose based on desired potency (ICS and ICS/LABA inhalers only)

- The following charts can be used to decide on the appropriate ICS dose based on the desired potency. The dose comparisons are suggestions from the GINA 2020 Report and do not imply equivalence.
- Of note, the dosing in the ICS only inhaler chart is expressed as the total daily dose and may need to be divided into multiple doses per day.
- LABA doses do not change with higher doses of ICS when used in combination. Patients that are prescribed ICS/LABA combination inhalers that need a higher ICS dose should be given a new prescription. Patients should not double the dose of their current inhaler.

Inhaled corticosteroid (ICS) only dose comparison chart					
Drug	Available strength (mcg)	Recommended frequency	Total daily ICS dose comparison (mcg)		
			Low	Medium	High
Alvesco HFA (ciclesonide)	80 160	BID	80-160	160-320	>320
ArmonAir Respiclick¹ (fluticasone)	55 113 232	BID	100-250	250-500	>500
Arnuity Ellipta (fluticasone furoate)	100 200	Daily	100		200
Asmanex HFA (mometasone)	100 200	BID	200-400		>400
Asmanex Twisthaler (mometasone)	110 220	Daily or BID	200		400
Flovent Diskus (fluticasone)	50 100 250	BID	100-250	250-500	>500
Flovent HFA (fluticasone)	44 110 220	BID	100-250	250-500	>500
Pulmicort Flexhaler (budesonide)	90 180	BID	200-400	400-800	>800
QVAR Redihaler (beclomethasone)	40 80	BID	100-200	200-400	>400

¹Studies suggest that the Respiclick device is able to deliver medication more efficiently than other DPI devices. Lower doses of fluticasone delivered by this device have demonstrated non-inferiority relative to other DPIs.

[Return to Page 1](#)

Inhaled corticosteroid/Long-acting beta agonist (ICS/LABA) dose comparison chart				
Drug	Recommended directions	ICS/LABA inhaler strength (mcg)		
		Low	Medium	High
Advair Diskus¹ (fluticasone/salmeterol)	1 puff BID	100/50	250/50	500/50 ²
Advair HFA² (fluticasone/salmeterol)	2 puffs BID	45/21	115/21	230/21
fluticasone/salmeterol MDPI^{1,2,3} (generic AirDuo Respiclick)	1 puff BID	55/14	113/14	232/14
Breo Ellipta (fluticasone furoate/ vilanterol)	1 puff daily	100/25		200/25 ²
Dulera HFA² (mometasone/formoterol)	2 puffs BID	N/A	100/5	200/5
Symbicort HFA¹ (budesonide/formoterol)	2 puffs BID	80/4.5	160/4.5	N/A
Wixela Inhub¹ (fluticasone/salmeterol)	1 puff BID	100/50	250/50	500/50 ²

¹Available generically, ² Drug/dose not indicated for use in COPD, ³Studies suggest that the Respiclick device is able to deliver medication more efficiently than other DPI devices. Lower doses of fluticasone delivered by this device have demonstrated non-inferiority relative to other DPIs.

Triple therapy (LAMA/LABA/ICS) dose comparison chart				
Drug	Recommended directions	LAMA/LABA/ICS inhaler strength (mcg)		
		Low	Medium	High
Trelegy Ellipta (umeclidinium/vilanterol/ fluticasone furoate)	1 puff daily	62.5/25/100		62.5/25/200 ²
Breztri Aerosphere¹ (glycopyrrolate/formoterol/ budesonide)	2 puffs BID	N/A	9/4.8/160	N/A

¹Drug not indicated for use in asthma, ²Dose not indicated for use in COPD

[Return to Page 1](#)

Section 5

Educate regarding proper inhaler technique


Proper adherence and technique is vital for the success of a patient's asthma treatment and is often overlooked. There are many different devices available which all have caveats to their use that make it difficult for patients to even know whether they are using them correctly. Upon prescribing of a new inhaler for patients, a plan should always be put in place for how the patient will be taught how to use the device. Please refer to the ***BILH Inhaler Step-by-Step Instructions*** reference, and consider the following approaches:

1. If available, providers and/or support staff are encouraged to demonstrate inhaler technique in the office. Placebo-filled device samples for office use are available to be requested through manufacturers. See step-by-step inhaler device teaching document for instructions for each inhaler device.
2. Technologically savvy patients can search for inhaler demonstration videos available online.
3. Patients may request a consultation with their local pharmacist upon picking up the prescription. Many pharmacies have sample devices they may use to demonstrate technique. Patients may also request to take their first dose in view of the pharmacist to get real-time feedback.
4. Consider telehealth follow-up for review and observation of inhaler technique. This may allow for closer follow-up without the need for an in-person visit. If the patient and provider are able to use video calling, this may make observation more beneficial for the patient.

[Return to Page 1](#)

Section 6
Reassess for proper adherence, technique and response

Reassessment Cycle



- All patients with asthma and/or COPD should be consistently assessed and reassessed for proper response to treatment, inhaler technique, and adherence.
- Per the GINA 2020 Report, patients initiated on asthma inhaler therapy should be seen within 1-3 months after starting treatment and every 3-12 months thereafter. Response to stepping up in therapy should be reviewed after 2-3 months.
- Per the 2021 GOLD Report, patients should be seen within 4 weeks and again at 12-16 weeks following an exacerbation.

Reassessment Cycle		
	Items	Action(s)
Review	Symptom control	Consider administering symptom questionnaire(s):
	Exacerbation history	- Asthma Control Test (ACT) or Asthma Control Questionnaire (ACQ)
	Lung function	- COPD Assessment Test (CAT) or the Modified Medical Research Council (mMRC) Dyspnea Scale
	Side effects	Administer pulmonary function tests (PFTs) as needed
	Patient satisfaction	Assess exacerbation history, adverse effects, and patient satisfaction via chart review and patient interviewing
Assess	Proper inhaler technique	Ask patient to bring inhaler to the follow-up appointment to demonstrate proper technique
	Proper adherence (pharmacologic and non-pharmacologic)	Call pharmacy to assess patient's inhaler refill history in order to confirm proper adherence and to assess for overuse of rescue inhalers
	Presence of triggers	Review non-pharmacologic recommendations (i.e., smoking cessation, vaccinations, and pulmonary rehabilitation) as appropriate
Adjust	Escalate or de-escalate therapy as needed	If symptomatic despite proper adherence and technique, consider stepping up therapy
	Consider different inhaler device or active ingredient	For patients managed with an ICS, consider stepping down therapy if good symptom control is maintained for at least 3 months.
	Educate on adherence and technique	- To reduce risk of adverse effects (i.e., pneumonia)
		- Goal is to achieve minimum effective ICS dose
		- GINA does not recommend managing asthma patients with only short-acting beta agonists (i.e., albuterol) at this time
		Education on the importance of appropriate inhaler technique and adherence should be stressed with every follow-up

[Return to Page 1](#)

References:

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Available from: www.ginasthma.org
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. <https://goldcopd.org/gold-reports/>

Tier coverage based on the following:

- BCBS: <https://home.bluecrossma.com/medication/med-search>
- HPHC: https://www.harvardpilgrim.org/portal/page?_pageid=253,13048065&_dad=portal&_schema=PORTAL
- Tufts: <https://tuftshealthplan.com/member/employer-individual-or-family-plans/plans-benefits/pharmacy-benefit/pharmacy-formularies>
- MassHealth: <https://masshealthdruglist.ehs.state.ma.us/MHDL/pubdownloadpdfcurrent.do?id=45>

Approval Dates:

BILH Ambulatory P&T Subcommittee: March 2021

BILH System P&T: April 2021

[Return to Page 1](#)